Skip to content
The Nexus
DossierENTITY

Ollin Biosciences

Coverage of Ollin Biosciences in the Nexus archive.

Earliest in view: Jun 24 · 11:00 UTCMost recent: Jun 24 · 11:00 UTC
Co-mentioned in this coverage
TCGXorganization1ARCH Venture Partnersorganization1diabetic macular edematopic1wet age-related macular degenerationtopic1
Recent coverage
  • BUSINESSJun 24 · 11:00 UTCSTAT NEWS
    STAT+: Ophthalmology venture grabs investors’ attention, raises $330 million

    Ollin Biosciences, a startup developing treatments for eye diseases, raised $330 million in a Series B funding round led by TCGX and ARCH Venture Partners. The company is preparing for a Phase 3 trial of a treatment targeting diabetic macular edema and wet age-related macular degeneration.

Ollin Biosciences · Dossier · The Nexus